Peptide Protocols: Dosing, Cycling, and Stacking

A peptide protocol sets the dose, frequency, cycle length and stacking plan for each peptide: growth hormone secretagogues such as ipamorelin and CJC-1295 are commonly run at bedtime, 5 days on and 2 days off, for 8 to 12 weeks followed by a 4 week break, while BPC-157 is usually given continuously for 4 to 12 weeks. For Vesugen, the Lys-Glu-Asp (KED) tripeptide developed at Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, no published human trial or FDA label sets an injection cycle length or a dose in mg per day, so any figure a seller quotes is unvalidated.

At a Glance

• Peptide protocols define how peptides are dosed, timed, cycled, and combined for specific therapeutic goals
• Some peptides require cycling (GH secretagogues) to prevent receptor desensitization, while others are used continuously until the goal is reached (BPC-157)
• Stacking means combining complementary peptides for synergistic effects: common examples include BPC-157 + TB-500 and Ipamorelin + CJC-1295
• “More is not better”: exceeding recommended doses typically increases side effects without proportional benefit
• Safety monitoring (bloodwork, IGF-1 levels) is essential for growth hormone-related protocols
• Protocols should be individualized by a knowledgeable practitioner based on your health goals, labs, and response

---

What Makes a Peptide Protocol?

A peptide protocol is the structured plan that defines exactly how a peptide, or a combination of peptides, is used to reach a specific therapeutic goal. It covers the dose, the frequency, the duration, cycling patterns, and any complementary peptides used together. Practitioners also call it a peptide regimen, a peptide cycle or, when several peptides run together, a peptide stack.

If the peptide is the tool, the protocol is the blueprint. The same peptide can produce very different results depending on how it is used. A BPC-157 protocol for healing a torn rotator cuff looks different from one targeting gut repair. An ipamorelin protocol for anti-aging optimization differs from one designed as a short-term recovery intervention.

Every protocol has the same five attributes: the peptide and its route (subcutaneous injection, intranasal spray or oral), the dose in mcg or mg, the frequency, the cycle length, and the stop rule. The route matters because it changes the dose: oral MK-677 is measured in mg, while injectable ipamorelin is measured in mcg.

The sections below explain how experienced practitioners structure peptide protocols, including the reasoning behind cycling, stacking, dosing schedules, and the monitoring that keeps risk in check. If you are new to peptide therapy, start with our thorough Peptide Therapy pillar guide before diving into protocol specifics, or read the peptide therapy treatment overview for how the therapy is offered in clinics.

Cycling: Why Timing On and Off Matters

Cycling refers to alternating periods of active peptide use (“on” periods) with rest periods (“off” periods). Not every peptide requires cycling, and knowing which ones do, and why, is central to a well run protocol.

Peptides That Benefit From Cycling

Growth hormone secretagogues (Ipamorelin, CJC-1295, GHRP-6, MK-677) are the primary category where cycling is important. The reason is receptor desensitization: with continuous, prolonged use, the receptors these peptides act on can become less responsive over time. You end up needing more to get the same effect, the classic pattern of diminishing returns.

A typical cycling pattern for GH secretagogues is 5 days on / 2 days off or 8-12 weeks on / 4 weeks off. The rest period allows receptor sensitivity to reset, so when you resume, the peptide works effectively at the same dose.

PT-141 (Bremelanotide) also requires spacing. The FDA recommends no more than 8 doses per month, and not more than one dose in 24 hours. Tachyphylaxis (rapid tolerance) can develop with too-frequent use.

Peptides That Typically Do Not Require Cycling

BPC-157 is generally used continuously throughout the healing period. Because it is thought to act through several mechanisms (angiogenesis promotion, growth factor modulation, nitric oxide system regulation) rather than a single receptor pathway, desensitization is not considered a major concern. Most practitioners prescribe it for a defined treatment course, typically 4 to 12 weeks, based on the injury being treated, then discontinue once healing goals are met. The BPC-157 dosage breakdown covers the dose ranges by injury type.

Thymosin Alpha-1 is often used in extended courses for immune modulation without cycling, as its mechanism of action does not appear to produce significant receptor desensitization.

Semaglutide is used continuously as a long-term therapy for weight management or metabolic health. Cycling is not part of the standard protocol, and discontinuation typically leads to weight regain if lifestyle modifications are not maintained.

Peptide	Cycling Needed?	Typical Pattern	Rationale
Ipamorelin	Yes	5 on / 2 off or 8-12 weeks on / 4 weeks off	Prevent GH receptor desensitization
CJC-1295 (no DAC)	Yes	Same as Ipamorelin (often paired)	Prevent GHRH receptor desensitization
CJC-1295 (with DAC)	Yes	8-12 weeks on / 4 weeks off	Long-acting: cycling prevents sustained receptor downregulation
MK-677	Recommended	8-12 weeks on / 4-8 weeks off	Sustained GH elevation may affect insulin sensitivity
BPC-157	No	Continuous for 4-12 weeks, then stop	Goal-based duration; no significant desensitization
TB-500	No (but phased)	Loading phase then maintenance (see below)	Front-loads healing stimulus, then tapers
Semaglutide	No	Ongoing as prescribed	Continuous use for sustained metabolic benefits
PT-141	Yes (by design)	As needed, max 8 doses/month	Tachyphylaxis with frequent use
Thymosin Alpha-1	No	Extended courses as prescribed	Immune modulation without significant desensitization
Selank / Semax	Optional	4-6 weeks on / 2-4 weeks off if cycling	Some practitioners cycle to assess ongoing need
Vesugen (KED)	No validated pattern	No published injectable cycle or mg per day dose	Evidence is mostly cell culture and small oral studies

Vesugen Protocols: Cycle Length and Dose per Day

Vesugen has no validated injection cycle length and no established dose in mg per day. It is a synthetic tripeptide, lysyl-glutamyl-aspartic acid (Lys-Glu-Asp, one letter code KED), and it belongs to the group of short "peptide bioregulators" developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The same family includes Epitalon (AEDG), Pinealon (EDR) and Vilon (KE).

What is Vesugen used for?

Vesugen is described in the Russian literature as a vasoprotective peptide aimed at the blood vessel lining (the vascular endothelium). According to Khavinson and colleagues (Advances in Gerontology, 2014), KED raised the proliferation marker Ki-67 in vascular endothelial cell cultures from young and old animals (PubMed 25051766). A later in vitro study by Kozlov and colleagues (2016) reported that KED normalized endothelin-1 expression in atherosclerotic and restenotic endothelium models (PubMed 28539025).

How long is a Vesugen cycle?

No peer reviewed human trial defines a Vesugen cycle. Khavinson's school generally gives bioregulators as short, intermittent courses separated by breaks rather than as continuous daily therapy, but the course lengths quoted by online sellers are not backed by published dose finding work. A 2021 review by Khavinson, Lin'kova and Umnov notes that the human reports used oral KED, in older adults with functional nervous system disorders (PubMed 34173097).

Is there an mg per day dose for Vesugen injections?

No. Vesugen has no FDA approval, no FDA label and no US dosing standard, and the injectable vials sold online are often labeled for research use only. Without pharmacokinetic studies in people, nobody can say how much injected KED reaches the vessel wall, how long it lasts, or what a safe ceiling is. A clinician asked about Vesugen should tell you plainly that any mg per day figure is an extrapolation, not a tested dose.

If your interest in Vesugen comes from circulation, blood pressure or vascular aging, a physician can order tests with established meaning, such as a lipid panel, HbA1c, blood pressure tracking or an ankle brachial index, before you consider an experimental bioregulator. Those results also give you a baseline to judge any protocol against.

Stacking: Combining Peptides for Synergistic Results

Stacking refers to using two or more peptides simultaneously, chosen to complement each other’s mechanisms. When done thoughtfully, stacking can produce results greater than either peptide alone. When done carelessly, it just increases cost and complexity without meaningful benefit.

Few stacks have been tested as combinations in controlled human trials. The stacks below are the ones practitioners use most often, and each is built on the known action of its individual peptides:

Stack 1: BPC-157 + TB-500 for Injury Healing

This is arguably the most popular peptide stack in regenerative medicine, often sold under the name Wolverine stack. The rationale is straightforward: BPC-157 and TB-500 promote tissue healing through different but complementary pathways in animal studies.

BPC-157 promotes angiogenesis (new blood vessel formation), modulates growth factor expression, and has strong anti-inflammatory effects concentrated at the site of injury in animal models. Most of this work comes from Predrag Sikiric's group at the University of Zagreb. The BPC-157 treatment page covers its uses for tendon, ligament, muscle and gut healing.

TB-500 (Thymosin Beta-4) is a synthetic fragment of thymosin beta-4 that promotes cell migration to injury sites, reduces inflammation systemically, and supports tissue remodeling in preclinical studies. It has a broader, more systemic healing effect. The TB-500 peptide overview explains how it differs from the full protein.

Together, they address both the localized healing environment (BPC-157) and the systemic recovery support (TB-500). Practitioners who use the combination report faster recovery than with either peptide alone, but no controlled human trial has compared the stack against its parts.

Typical protocol: BPC-157 at 250-500mcg twice daily (SubQ, ideally near the injury), plus TB-500 at 750mcg twice weekly for the first 4-6 weeks (loading), then 750mcg once weekly for maintenance. Duration: 6-12 weeks depending on the injury.

Stack 2: Ipamorelin + CJC-1295 (no DAC) for Growth Hormone Optimization

This is the most widely used combination for stimulating your body’s own growth hormone production. The two peptides work on different receptors in the GH signaling cascade:

CJC-1295 (without DAC) is a GHRH (growth hormone-releasing hormone) analog. It acts on the GHRH receptor in the pituitary to prime the system for GH release. The long-acting version with DAC behaves differently: according to Teichman and colleagues (Journal of Clinical Endocrinology and Metabolism, 2006), a single injection raised GH for 6 days or more and had an estimated half-life of 5.8 to 8.1 days (PubMed 16352683).

Ipamorelin is a ghrelin mimetic that acts on the GHS receptor. It provides the direct “pulse” signal to release growth hormone. Raun and colleagues (European Journal of Endocrinology, 1998) described it as the first selective GH secretagogue, because in swine it released GH without raising ACTH or cortisol the way GHRP-6 and GHRP-2 did (PubMed 9849822).

Think of CJC-1295 as setting the stage and ipamorelin as triggering the curtain rise. Together, they are intended to produce a stronger, more physiological GH pulse than either peptide alone, without the broad hormonal effects of synthetic HGH. The CJC-1295 and ipamorelin guide covers timing and side effects in more depth.

Typical protocol: CJC-1295 at 100mcg + Ipamorelin at 200-300mcg, combined in the same syringe, injected SubQ at bedtime on an empty stomach. 5 days on / 2 days off. Cycle: 8-12 weeks on, 4 weeks off.

Stack 3: Selank + Semax for Cognitive Support

For cognitive optimization, this Russian-developed duo targets different but complementary neural pathways. Both are registered medicines in Russia and neither is FDA approved.

Selank is derived from tuftsin and has anxiolytic (anti-anxiety) properties plus immune-modulating effects. It supports cognitive function by reducing the background noise of anxiety and stress that impairs focus and memory. See the Selank peptide guide for the research behind it.

Semax is derived from ACTH(4-10) and has direct nootropic and neuroprotective effects. It enhances BDNF (brain-derived neurotrophic factor) expression, supports attention and memory, and has been used clinically in Russia for cognitive decline and stroke recovery. The Semax overview covers its intranasal use.

Together, Selank calms and stabilizes while Semax sharpens, a combination that many users describe as “clear-headed focus without jitteriness.” That description comes from user reports, not from trials of the pair.

Typical protocol: Selank 300-600mcg intranasally, 2-3 times daily. Semax 200-600mcg intranasally, 2-3 times daily. Often used in 4-6 week courses. Both are nasal sprays, so no injection is needed.

Stack 4: BPC-157 + Ipamorelin + CJC-1295 for Healing and Recovery

This triple stack is sometimes used for athletes or individuals recovering from significant injury or surgery where both faster tissue healing and the regenerative benefits of optimized growth hormone are desired. The GH secretagogues support the systemic recovery environment while BPC-157 targets localized tissue repair.

Typical protocol: BPC-157 at 250-500mcg twice daily (ongoing), plus Ipamorelin 200-300mcg + CJC-1295 100mcg at bedtime (cycled 5/2). Duration depends on recovery needs, typically 8-12 weeks.

Key Concept: More Is Not Better

One of the most important principles in peptide therapy is that exceeding recommended doses does not produce proportionally better results, but it does produce proportionally more side effects. Growth hormone secretagogues at excessive doses can cause water retention, joint pain, carpal tunnel symptoms, and insulin resistance. BPC-157 at megadoses has not been shown to heal faster than standard doses. Stick to evidence-based dosing ranges and give the protocol time. The body’s receptor systems have saturation points, and pushing past them creates diminishing returns at increasing cost to your comfort and safety.

Comprehensive Dosing Schedule Reference

The table lists the dose, frequency, timing and duration practitioners most often use for each major peptide. Only semaglutide and PT-141 follow an FDA approved label; every other row reflects common clinical practice rather than a regulator approved schedule.

Peptide	Typical Dose	Frequency	Timing	Duration
BPC-157	250-500mcg	2x daily	Morning and evening	4-12 weeks (until healed)
TB-500	750mcg	2x/week (loading), 1x/week (maint.)	Any time	6-12 weeks
Ipamorelin	200-300mcg	1x daily, 5 days on / 2 off	Bedtime, empty stomach	8-12 weeks, then 4 weeks off
CJC-1295 (no DAC)	100mcg	1x daily, 5 days on / 2 off	Bedtime, with Ipamorelin	8-12 weeks, then 4 weeks off
CJC-1295 (with DAC)	1,000-2,000mcg	1-2x per week	Any time	8-12 weeks, then 4 weeks off
MK-677	10-25mg (oral)	1x daily	Bedtime	8-12 weeks on, 4-8 weeks off
Semaglutide	0.25mg-2.4mg	1x per week	Same day each week	Ongoing as prescribed
PT-141	1.75mg	As needed	45 min before activity	Max 8 doses/month
Thymosin Alpha-1	1.6mg	2-3x per week	Any time	Extended courses as prescribed
Selank	300-600mcg	2-3x daily (intranasal)	As needed throughout day	4-6 week courses
Semax	200-600mcg	2-3x daily (intranasal)	Morning and afternoon	4-6 week courses
Vesugen (KED)	No established dose	Not defined in human trials	Not defined	No validated cycle

⚠ Safety Warning: These Are General Ranges, Not Prescriptions

The dosing information on this page represents commonly reported clinical ranges for educational purposes. Individual dosing should always be determined by your prescribing practitioner based on your body weight, health status, goals, lab results, and response to therapy. Do not self-prescribe peptide protocols based on internet information alone.

Loading vs. Maintenance Phases

Several peptide protocols distinguish between an initial loading phase and an ongoing maintenance phase. This approach front-loads the therapeutic stimulus to establish an effect, then reduces the dose or frequency to sustain it.

TB-500 Loading Protocol

TB-500 is the classic example of a loading/maintenance approach:

• Loading (Weeks 1-6): 750mcg injected subcutaneously, twice per week
• Maintenance (Weeks 7+): 750mcg once per week, or every two weeks depending on response

The loading phase is meant to establish the healing stimulus quickly. The maintenance phase sustains the effect at a lower input. This schedule comes from clinical practice, not from human dose finding trials.

Semaglutide Dose Titration

Semaglutide, a GLP-1 receptor agonist, uses a graduated dose escalation rather than a true loading/maintenance split, but the principle is similar: start low to allow the body to adapt. This is the schedule used in the STEP 1 trial of once-weekly semaglutide 2.4 mg in adults with overweight or obesity (Wilding et al., New England Journal of Medicine, 2021; PubMed 33567185):

• Weeks 1-4: 0.25mg once weekly
• Weeks 5-8: 0.5mg once weekly
• Weeks 9-12: 1.0mg once weekly
• Week 13+: 1.7mg or 2.4mg once weekly (if needed and tolerated)

This titration schedule reduces gastrointestinal side effects compared to starting at the full therapeutic dose. Compounded versions follow the same logic; the compounded semaglutide page explains how they differ from the approved product, and the semaglutide side effects guide covers what to watch for during each step.

What Does the Research Support for Each Peptide?

The evidence behind peptide protocols ranges from large FDA reviewed trials to cell culture studies. Semaglutide and bremelanotide have FDA approved labels for specific uses. Most other peptides in common protocols are used off label or are not approved at all, and much of their data comes from animal studies or small trials.

The FDA's list of bulk drug substances that may present significant safety risks in compounding (category 2, current as of April 2026) still includes ipamorelin acetate, GHRP-6 and ibutamoren mesylate (MK-677). The same page lists BPC-157, CJC-1295, TB-500, thymosin alpha-1, Selank and Semax as substances previously in category 2 whose nominations were withdrawn, with the FDA's safety concerns still published beside each one.

Peptide	US regulatory status	Strongest published evidence
Semaglutide	FDA approved for type 2 diabetes and chronic weight management	Large randomized trials, including STEP 1 (Wilding et al., 2021)
PT-141 (bremelanotide)	FDA approved (2019) for hypoactive sexual desire disorder in premenopausal women	Phase 3 trials reviewed by the FDA
CJC-1295	Not FDA approved	Small dose ranging trials in healthy adults (Teichman et al., 2006)
Ipamorelin	Not FDA approved; FDA compounding category 2	Animal pharmacology (Raun et al., 1998) and limited human data
MK-677 (ibutamoren)	Not FDA approved; FDA compounding category 2	One year randomized trial in older adults (Nass et al., 2008)
BPC-157	Not FDA approved	Mostly animal studies; very limited human data
TB-500	Not FDA approved	Preclinical studies of thymosin beta-4
Thymosin Alpha-1	Not FDA approved; approved in several other countries	Clinical studies abroad, mainly in hepatitis B and immune support
Selank / Semax	Not FDA approved; registered in Russia	Mostly Russian clinical and laboratory studies
Vesugen (KED)	Not FDA approved	Cell culture and small Russian studies (Khavinson et al.)

MK-677 shows why this matters. In a 12 month trial in 65 healthy adults aged 60 to 81, Nass and colleagues (Annals of Internal Medicine, 2008) found that 25 mg daily raised GH and IGF-1 and increased fat-free mass, but fasting glucose rose and insulin sensitivity fell (PubMed 18981485). The FDA also cites a separate ibutamoren trial in hip fracture patients that was stopped early for a possible congestive heart failure signal.

How to Assess Your Response

Knowing whether your protocol is working requires both subjective and objective tracking:

Subjective markers:

• Sleep quality (especially with GH secretagogues, where improved deep sleep is often the first noticeable change)
• Recovery speed from exercise or injury
• Pain levels (for healing protocols)
• Energy, focus, and mood (cognitive peptides)
• Body composition changes (skin quality, fat distribution, muscle tone)
• Appetite and satiety (weight loss peptides)

Objective markers (lab work):

• IGF-1 levels: The primary monitoring lab for GH secretagogues. Target range depends on age, but most practitioners aim for the upper-normal range (200-300 ng/mL for most adults). Levels above 350 ng/mL may warrant dose reduction.
• Fasting glucose and HbA1c: GH peptides and MK-677 can affect insulin sensitivity. Monitoring shows whether metabolic health is holding steady.
• Comprehensive metabolic panel: Baseline organ function markers to confirm nothing unexpected is shifting.
• Imaging: For injury protocols, follow-up MRI or ultrasound can objectively document healing progress.

When to Stop or Modify a Protocol

Peptide protocols are not indefinite commitments. Knowing when to stop is as important as knowing how to start.

Stop or modify when:

• The therapeutic goal is met. If BPC-157 was prescribed for tendon healing and the tendon has healed, discontinue. Do not continue “just because.”
• Side effects become problematic. Water retention, joint pain, persistent nausea, or any unexpected symptom warrants a conversation with your provider about dose adjustment or discontinuation.
• Lab markers move out of range. IGF-1 climbing too high, fasting glucose rising, or any concerning lab change means the protocol needs adjustment.
• No measurable benefit after adequate trial. If you have been on a protocol for the expected response timeframe (usually 4-8 weeks minimum) with no subjective or objective improvement, the protocol may not be the right approach for you.
• A new health condition arises. A cancer diagnosis, pregnancy, or other significant health change may contraindicate continued use of certain peptides.

Safety Monitoring by Protocol Type

Protocol Type	Key Labs to Monitor	Monitoring Frequency	Red Flags
GH Secretagogues	IGF-1, fasting glucose, HbA1c, insulin	Baseline, 6 weeks, then every 3 months	IGF-1 >350, rising fasting glucose, new joint pain
Healing (BPC-157, TB-500)	CMP (baseline), imaging if applicable	Baseline; imaging as clinically indicated	Unusual pain, signs of infection at injection site
Weight Loss (Semaglutide)	CMP, lipase/amylase, thyroid panel, kidney function	Baseline, 3 months, then every 6 months	Severe GI symptoms, persistent abdominal pain (pancreatitis risk)
Immune (Ta1)	CBC with differential, CMP	Baseline, 4-6 weeks	Unexpected immune activation or suppression
Cognitive (Selank, Semax)	Minimal: baseline CMP recommended	Baseline	Mood changes, paradoxical anxiety increase

The schedule above reflects common practice, not a published guideline. Your prescriber may test more often if you have diabetes, a history of cancer, kidney disease or heart failure, or if you are on several peptides at once. The peptide safety evidence review grades the risks peptide by peptide.

How to Manage a Peptide Protocol Safely

Safe peptide protocol management rests on six habits: a licensed prescriber, a known pharmacy source, baseline labs, sterile technique, a written stop rule and scheduled follow-up. Each one closes a gap that self-directed protocols usually leave open.

1. Use a licensed prescriber. A physician (MD or DO), nurse practitioner or physician assistant can screen your history, medications and labs before writing a protocol.
2. Know the source. Prescription peptides in the US come from state licensed 503A compounding pharmacies or 503B outsourcing facilities. Vials labeled "for research use only" are not made or tested for human use.
3. Get baseline labs. IGF-1, fasting glucose, HbA1c and a comprehensive metabolic panel give you a reference point before the first dose.
4. Use sterile technique. Reconstitute with bacteriostatic water, store vials as directed, rotate subcutaneous injection sites and never share needles. The peptide injection technique guide walks through reconstitution and dosing math.
5. Write down the stop rule. Agree in advance on the goal, the maximum duration and the lab values or side effects that end the protocol.
6. Schedule follow-up. Book the 6 week and 3 month check-ins when you start, so dose changes are based on data rather than impressions.

Who should not start a peptide protocol?

People who are pregnant or breastfeeding, people with active cancer or a recent cancer history, and people with poorly controlled diabetes are usually advised against growth hormone secretagogues, because these peptides raise IGF-1 and can raise blood glucose. Semaglutide carries its own label warnings, including for people with a personal or family history of medullary thyroid carcinoma. Competitive athletes should know that the World Anti-Doping Agency prohibits BPC-157, TB-500 and growth hormone secretagogues in tested sport.

Who prescribes peptide protocols?

Peptide protocols in the US are most often written by physicians in integrative, functional, sports and longevity medicine, by nurse practitioners and physician assistants, and in some states by naturopathic doctors with prescribing rights. Endocrinologists usually prescribe only the FDA approved peptides. Most peptide protocols are cash pay, and insurance rarely covers off label or unapproved peptides.

To compare providers, browse the national list of peptide therapy clinics and ask each one how it sources peptides and which labs it orders. Regenerated.com is free for patients. Listing order is not paid ranking, Featured slots are labeled and capped, and Verified means a clinic completed credential checks, not that it spent money. Inclusion in the directory is not an endorsement, and the guide to Featured, Verified and organic listings explains each label.

Frequently Asked Questions

Can I combine peptides from different categories?

Yes, practitioners commonly combine categories when there is a clinical reason. A healing stack (BPC-157 + TB-500) can run alongside a GH secretagogue stack (Ipamorelin + CJC-1295), for example after surgery, when both local tissue repair and systemic recovery matter. Every added peptide adds cost, side effect risk and lab monitoring, and few combinations have been tested together in human trials. Ask your practitioner whether a simpler protocol would reach the same goal.

How long until I notice results?

Results usually appear within 1 to 12 weeks, depending on the peptide. GH secretagogues often improve sleep within 1 to 2 weeks, with body composition changes over 8 to 12 weeks. BPC-157 for injury may show improvement within 2 to 4 weeks. Semaglutide typically produces measurable weight loss within 4 to 8 weeks at therapeutic doses. Selank and Semax often produce subjective effects within days. Give a protocol its full trial period before judging it.

Can I mix peptides in the same syringe?

Some peptides can share a syringe, and Ipamorelin with CJC-1295 (no DAC) is the most common example. Mixing works only when both peptides are in aqueous solution at compatible pH levels. Other combinations can degrade or precipitate when drawn together, which can weaken the dose or irritate the injection site. Confirm compatibility with your prescriber or compounding pharmacist before mixing any two peptides.

What happens during the “off” period of a cycle?

During the off period of a GH secretagogue cycle, growth hormone levels drift back toward baseline. You may notice a slight drop in sleep quality or recovery speed, which is normal and expected. The break allows receptor sensitivity to reset so the peptide works at the same dose when you resume. Many practitioners use the off weeks to recheck IGF-1 and fasting glucose, and recommend keeping sleep, exercise and nutrition habits steady throughout.

Do I need a practitioner, or can I design my own protocol?

A practitioner experienced in peptide therapy is strongly recommended. A safe protocol depends on your health history, current medications, lab results and goals, and a clinician can screen for contraindications you may not know about, adjust dosing based on your response and order the right follow-up labs. Self-prescribing from online research adds avoidable risk, especially with unapproved peptides. For more on the safety considerations, see our detailed guide on peptide safety.

How long is a Vesugen cycle, and what is the dose in mg per day?

No validated Vesugen cycle length or mg per day dose exists. Vesugen (Lys-Glu-Asp, or KED) is a bioregulator tripeptide from Vladimir Khavinson's St. Petersburg institute, and its published research is mostly cell culture work and small oral studies in older adults. No human trial has tested injectable doses, and the FDA has not approved it for any use. Treat any injection schedule quoted online as unverified, and discuss vascular concerns with a physician.

Building Your Protocol: A Summary Framework

1. Define the goal. Healing? GH optimization? Cognitive enhancement? Weight management? Immune support? The goal determines everything else.
2. Select the peptide(s). Choose the minimum number of peptides needed to achieve your goal effectively. Resist the urge to add peptides without clear rationale, and favor peptides with published human data.
3. Establish baseline labs. Before starting, get appropriate bloodwork so you have a comparison point for monitoring.
4. Start at conservative doses. Begin at the lower end of the dosing range and titrate up based on tolerability and response.
5. Set the schedule. Determine dosing frequency, cycling pattern (if applicable), and total planned duration. For GH secretagogues that often means 5 days on and 2 off for 8 to 12 weeks, then 4 weeks off.
6. Track your response. Keep a simple log of subjective markers. Schedule follow-up labs at appropriate intervals.
7. Adjust or stop as needed. Protocols are living documents. Modify based on response, side effects, or changing goals.

Related Reading

• Peptide Therapy: The Complete Guide: Our thorough pillar guide covering every major peptide category, mechanisms, and clinical applications
• Are Peptides Safe? What the Research Says: Detailed safety analysis, evidence grading, contraindications, and source quality guidance
• Peptide Injections: Types, Benefits, and How to Self-Inject: Practical injection guide with reconstitution instructions, dosing math, and technique
• Thymosin Alpha-1: How the immune peptide is dosed in extended courses and where it is approved outside the US
• PT-141 (Bremelanotide): The FDA approved dosing limits and how the peptide works on desire